Thompson Investment Management Inc. Acquires 150 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Thompson Investment Management Inc. increased its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZFree Report) by 2.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 6,670 shares of the specialty pharmaceutical company’s stock after purchasing an additional 150 shares during the quarter. Thompson Investment Management Inc.’s holdings in Jazz Pharmaceuticals were worth $803,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of JAZZ. HighTower Advisors LLC increased its position in Jazz Pharmaceuticals by 26.6% during the third quarter. HighTower Advisors LLC now owns 5,332 shares of the specialty pharmaceutical company’s stock valued at $696,000 after acquiring an additional 1,120 shares during the last quarter. Rafferty Asset Management LLC increased its position in Jazz Pharmaceuticals by 6.7% in the third quarter. Rafferty Asset Management LLC now owns 2,697 shares of the specialty pharmaceutical company’s stock worth $349,000 after buying an additional 170 shares in the last quarter. QRG Capital Management Inc. purchased a new stake in Jazz Pharmaceuticals in the third quarter worth about $290,000. Envestnet Portfolio Solutions Inc. purchased a new stake in Jazz Pharmaceuticals in the third quarter worth about $338,000. Finally, Envestnet Asset Management Inc. increased its position in Jazz Pharmaceuticals by 40.6% in the third quarter. Envestnet Asset Management Inc. now owns 61,463 shares of the specialty pharmaceutical company’s stock worth $7,956,000 after buying an additional 17,758 shares in the last quarter. 89.14% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, EVP Neena M. Patil sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $109.65, for a total value of $548,250.00. Following the transaction, the executive vice president now directly owns 36,629 shares in the company, valued at $4,016,369.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.20% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on JAZZ shares. Truist Financial reaffirmed a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 20th. JPMorgan Chase & Co. raised their price target on Jazz Pharmaceuticals from $170.00 to $190.00 and gave the stock an “overweight” rating in a research note on Friday, March 22nd. Piper Sandler raised their price target on Jazz Pharmaceuticals from $171.00 to $188.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 20th. The Goldman Sachs Group began coverage on Jazz Pharmaceuticals in a research note on Wednesday, June 5th. They set a “buy” rating and a $169.00 price target for the company. Finally, StockNews.com lowered Jazz Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, June 19th. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $190.00.

Check Out Our Latest Report on JAZZ

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock traded down $1.75 on Tuesday, hitting $108.08. The company had a trading volume of 668,106 shares, compared to its average volume of 696,758. The firm has a market cap of $6.82 billion, a P/E ratio of 22.65, a price-to-earnings-growth ratio of 1.66 and a beta of 0.62. The company has a 50-day moving average price of $109.06 and a 200-day moving average price of $117.10. The company has a quick ratio of 1.90, a current ratio of 2.27 and a debt-to-equity ratio of 1.38. Jazz Pharmaceuticals plc has a twelve month low of $103.01 and a twelve month high of $146.70.

Jazz Pharmaceuticals (NASDAQ:JAZZGet Free Report) last announced its quarterly earnings results on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share for the quarter, missing the consensus estimate of $3.53 by ($1.55). Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. The business had revenue of $901.98 million during the quarter, compared to analysts’ expectations of $938.99 million. As a group, equities research analysts predict that Jazz Pharmaceuticals plc will post 15.35 earnings per share for the current fiscal year.

About Jazz Pharmaceuticals

(Free Report)

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

See Also

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.